This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Aceragen Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Aceragen.

Informazioni chiave

n/a

Tasso di crescita degli utili

85.2%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	29.0%
Tasso di crescita dei ricavi	-161.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	01 Mar 2023

Aggiornamenti recenti sulla crescita futura

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31

Recent updates

Idera Pharmaceuticals completes acquisition of Aceragen

Sep 28

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Aug 24

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

May 11

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

Mar 07

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Jan 31

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Jan 13

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Dec 27

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Dec 27

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

Dec 15

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ACGN - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	N/A	-63	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
3/31/2023	7	-41	-30	-30	N/A
12/31/2022	5	-23	-24	-24	N/A
9/30/2022	0	-16	-15	-15	N/A
6/30/2022	N/A	-18	-17	-17	N/A
3/31/2022	N/A	-20	-20	-20	N/A
12/31/2021	N/A	97	-25	-25	N/A
9/30/2021	N/A	24	-28	-28	N/A
6/30/2021	N/A	9	-31	-31	N/A
3/31/2021	N/A	-8	-33	-33	N/A
12/31/2020	N/A	-113	-34	-34	N/A
9/30/2020	N/A	-87	-37	-37	N/A
6/30/2020	N/A	-78	-40	-40	N/A
3/31/2020	1	-65	-42	-42	N/A
12/31/2019	1	-85	-45	-44	N/A
9/30/2019	2	-45	-46	-46	N/A
6/30/2019	2	-46	-47	-47	N/A
3/31/2019	0	-51	-51	-51	N/A
12/31/2018	1	-60	-52	-52	N/A
9/30/2018	1	-63	-52	-52	N/A
6/30/2018	1	-66	-52	-52	N/A
3/31/2018	1	-71	-53	-52	N/A
12/31/2017	1	-66	-55	-55	N/A
9/30/2017	16	-50	-39	-39	N/A
6/30/2017	16	-49	-38	-38	N/A
3/31/2017	16	-41	-33	-33	N/A
12/31/2016	16	-38	N/A	-28	N/A
9/30/2016	1	-51	N/A	-42	N/A
6/30/2016	1	-50	N/A	-43	N/A
3/31/2016	1	-49	N/A	-43	N/A
12/31/2015	0	-49	N/A	-43	N/A
9/30/2015	0	-49	N/A	-44	N/A
6/30/2015	0	-47	N/A	-40	N/A
3/31/2015	0	-42	N/A	-36	N/A
12/31/2014	0	-39	N/A	-31	N/A
9/30/2014	0	-34	N/A	-26	N/A
6/30/2014	0	-29	N/A	-23	N/A
3/31/2014	0	-26	N/A	-21	N/A
12/31/2013	0	-21	N/A	-17	N/A
9/30/2013	0	-21	N/A	-17	N/A
6/30/2013	0	-21	N/A	-17	N/A
3/31/2013	0	-19	N/A	-18	N/A
12/31/2012	0	-22	N/A	-20	N/A
9/30/2012	0	-26	N/A	-19	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if ACGN's forecast earnings growth is above the savings rate (2.2%).

Guadagni vs Mercato: Insufficient data to determine if ACGN's earnings are forecast to grow faster than the US market

Guadagni ad alta crescita: Insufficient data to determine if ACGN's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: ACGN is forecast to have no revenue next year.

Ricavi ad alta crescita: ACGN is forecast to have no revenue next year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if ACGN's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Aceragen Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 88% to US$17.00

Price target increased to US$8.60

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

Recent updates

Price target decreased by 88% to US$17.00

Aceragen Receives Nasdaq Notice Regarding Delayed Form 10-Q Filing

Aceragen, Inc. announced delayed 10-Q filing

Aceragen, Inc. Announces John Kirby No Longer Serves as Chief Financial Officer

Aceragen, Inc. Announces Recommendation of Data Monitoring Committee in Terra Study

Aceragen, Inc. Announces Bryant D. Lim to Leave as Senior Vice President, Chief Business Officer and General Counsel of the Company, Effective February 17, 2023

Idera Pharmaceuticals Receives Notification of Non-Compliance from Listing Qualifications Department of Nasdaq

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA) acquired Aceragen, Inc.

Idera Pharmaceuticals completes acquisition of Aceragen

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

Insufficient new directors

Idera Pharmaceuticals Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients At Amsterdam UMC

We Think Idera Pharmaceuticals (NASDAQ:IDRA) Needs To Drive Business Growth Carefully

Insufficient new directors

Idera Pharmaceuticals, Inc., Annual General Meeting, Jun 23, 2022

Idera Pharmaceuticals, Inc. Announces Tilsotolimod Updates

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Growth Index

Senior VP & COO recently bought US$60k worth of stock

Independent Chairman recently bought US$101k worth of stock

Senior VP & Chief Medical Officer has left the company

Idera Pharmaceuticals Announces Corporate Updates

Idera Pharmaceuticals, Inc. Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma

Price target increased to US$8.60

Is Idera Pharmaceuticals (NASDAQ:IDRA) In A Good Position To Deliver On Growth Plans?

When Will Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Become Profitable?

New 90-day high: US$5.40

Idera outlines capital requirement to move tilsotolimod toward commercialization in advanced melanoma

Idera Pharmaceuticals, Inc. Announces Resignation of R. Clayton Fletcher as Senior Vice President

Could The Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ownership Structure Tell Us Something Useful?

Don't Ignore The Fact That This Insider Just Sold Some Shares In Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

President recently sold US$161k worth of stock

President notifies of intention to sell stock

Idera Pharmaceuticals receives $5M in additional proceeds from private placement

We're Keeping An Eye On Idera Pharmaceuticals' (NASDAQ:IDRA) Cash Burn Rate

New 90-day high: US$3.33

Idera Pharmaceuticals, Inc. Announces Board Changes

Idera Pharma names new operations chief

Earnings beat expectations

Idera Pharmaceuticals EPS misses by $0.37

New 90-day high: US$2.69

New 90-day high: US$2.68

Idera Pharmaceuticals, Inc. announced that it has received $5.1 million in funding

New 90-day high - US$2.22

Idera Pharmaceuticals, Inc.(NasdaqCM:IDRA) dropped from Russell Microcap Value Index

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita